Anavex Life Sciences financials
$2.02−14.41%
Close Sep 30, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q3 '26 Jun 30 | Q2 '26 Mar 31 | Q1 '26 Dec 31 | Q4 '25 Sep 30 | Q3 '25 Jun 30 | Q2 '25 Mar 31 | Q1 '25 Dec 31 | Q4 '24 Sep 30 | Q3 '24 Jun 30 | Q2 '24 Mar 31 | Q1 '24 Dec 31 | Q4 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross profit | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross margin | — | — | — | — | — | — | — | — | — | — | — | — |
| Operating income | $6.7M | -$6.5M | -$6.8M | -$10.8M | -$14.5M | -$12.5M | -$13.6M | -$14.3M | -$14.6M | -$12.6M | -$11.4M | -$12.7M |
| Net income | $7.8M | -$5.3M | -$5.7M | -$9.8M | -$13.2M | -$11.2M | -$12.1M | -$11.6M | -$12.2M | -$10.5M | -$8.6M | -$10.1M |
| Net margin | — | — | — | — | — | — | — | — | — | — | — | — |
| Diluted EPS | $0.08 | $-0.06 | $-0.06 | $-0.11 | $-0.16 | $-0.13 | $-0.14 | $-0.14 | $-0.14 | $-0.13 | $-0.11 | $-0.12 |
| EBITDA | $6.7M | -$6.5M | -$6.8M | -$10.8M | -$14.5M | -$12.5M | -$13.6M | -$14.3M | -$14.6M | -$12.6M | -$11.4M | -$12.7M |
| Operating cash flow | -$9.1M | -$4.4M | -$7.2M | -$8.6M | -$12.5M | -$5.9M | -$12.1M | -$6.7M | -$5.2M | -$11.7M | -$7.3M | -$5.8M |
| Free cash flow | -$9.1M | -$4.4M | -$7.2M | -$8.6M | -$12.5M | -$5.9M | -$12.1M | -$6.7M | -$5.2M | -$11.7M | -$7.3M | -$5.8M |
| Diluted shares | 92.9M | 92.7M | 89.0M | 85.9M | 85.4M | 85.1M | 84.8M | 84.8M | 84.5M | 82.5M | 82.1M | 82.0M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $118.3M | $127.4M | $131.7M | $102.6M | $101.2M | $115.8M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $120.1M | $128.8M | $133.0M | $103.8M | $102.4M | $117.1M |
| Total liabilities | $7.7M | $7.1M | $6.4M | $8.9M | $11.5M | $17.4M |
| Shareholders' equity | $112.4M | $121.7M | $126.6M | $94.9M | $91.0M | $99.8M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology